Talk to us.

Utilizing gene therapy to combat age-related diseases.

Rejuvenate Bio addresses the major cause of aging and age-related diseases by manipulating gene expression. Over time, gene expression dysregulates, leading multiple systems in the body to break down. Gene therapy addresses this by expressing beneficial proteins by directly introducing DNA to the cell, eliminating off-target effects. By using longevity-based genes, the company is able to offer therapies with robust safety profiles to specific, chronic conditions. 

Quick Facts for Investors

Location San Diego, CA
VCapital Invested 2021
CEO Daniel Oliver
Founded 2018
Founded By George Church PhD, Daniel Oliver MBA, Noah Davidsohn PhD
Industry Biotech

Why We Invested

 Rarely does an opportunity exist to monetize animal trials while conducting research for human trials and applications. The combination of talent on this leadership team represents VCapital’s belief that the jockey is as important as the horse in analyzing potential for success. 

 The total addressable market (TAM) for Rejuvenate Bio’s therapy is significant. Sixty-seven percent of U.S. households, or about 85 million families, own a pet, according to the 2019-2020 National Pet Owners Survey conducted by the American Pet Products Association (APPA). Currently, there are 90 million dogs owned as pets in the United States. Seven percent of all dogs will develop MVD, representing a market valued at $4.2B. The current standard of care for MVD is a small molecule, Vetmedin from Boehringer Ingelheim, that does not cure the actual disease but has proven to reduce symptoms. Vetmedin generates approximately $100 million of revenue annually. Rejuvenate Bio’s recent results show that their therapy not only stopped progression of MVD, but also reversed it. We believe demand for Rejuvenate Bio’s treatment will be significant. Currently, the company has partnered with the American Cavalier King Charles Club to run a pilot trial for cavaliers and estimates that they can reach 70% of the top-end pet health market.

News and Updates

June 28, 2024
CIRM awards $26 million to advance clinical research across cancer, heart conditions, and rare diseases
April 22, 2024
Rejuvenate Bio to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
March 8, 2024
The battle against the aging process
February 28, 2024
Rejuvenate Bio shows epigenetic reprogramming extends lifespan in normal mice
February 22, 2024
Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in the Journal Cellular Reprogramming
February 14, 2024
Rejuvenate Bio Announces Partnership with Leading Animal Health Company to Develop Gene Therapy for Canine Osteoarthritis
October 9, 2023
Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy
March 14, 2023
Rejuvenate Bio: Gene Therapy To Reverse Aging In Elderly Mice
January 9, 2023
This biotech startup says mice live longer after genetic reprogramming
January 9, 2023
Rejuvenate Bio Announces New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal
January 3, 2023
Rejuvenate Bio Appoints Deborah Ascheim, M.D., as Chief Medical Officer
November 30, 2022
Rejuvenate Bio Finds a Home in Sorrento Valley
June 24, 2022
Pet Biotech Roundtable
June 22, 2022
Phibro Animal Health Corporation and Rejuvenate Bio Announce Agreement to Develop Gene Therapy for Mitral Valve Disease in Canines
October 6, 2021
Rejuvenate Bio is Reversing Age-Related Diseases to Increase Healthspan
July 13, 2021
Rejuvenate Bio is hiring!
April 19, 2021
Fierce Biotech: Rejuvenate Bio banks $10M to advance gene therapy for aging in humans and dogs
April 19, 2021
Rejuvenate Bio Raises Over $10M in Series A Funding for Gene Therapy Aging Treatment
March 4, 2021
Len Batterson Ponders Human Regeneration
November 4, 2019
WSJ- A New Approach to Gene Therapy, Now in Dogs, Maybe Later in Humans